MedPath

HIIT on Overweight Middle-aged Adults

Not Applicable
Completed
Conditions
Overweight or Obesity
Interventions
Other: L-HIIT
Other: M-HIIT
Registration Number
NCT06383442
Lead Sponsor
Taipei Medical University
Brief Summary

36 middle-aged with overweight adults were divided into three groups: 1. L-HIIT group: the long-interval HIIT group (4 × 4 min Exercise/4 min Rest), 2. M-HIIT group: the medium-interval HIIT group (8 × 2 min Exercise/2 min Rest), 3. Control group: no exercise intervention. All groups carried out the training stage for 8 weeks (three sessions per week) and the detraining stage for 4 weeks in order to investigate the effects induced by different HIIT interventions on inflammation, metabolic adaptation, anti-fatigue and exercise performance, and fat loss.

Detailed Description

Aging, obesity, have been shown to lead to higher oxidative stress and chronic inflammation. However, high-intensity interval training (HIIT) has anti-inflammatory and anti-obesity benefits. Different training prescriptions may also affect improvements. Therefore, this study will explore the optimal HIIT prescription to improve fat, inflammation, metabolism, and exercise performance in overweight middle-aged and older adults. Thirty-six middle-aged with overweight adults were divided into three groups: 1. L-HIIT group: the long-interval HIIT group (4 × 4 min Exercise/4 min Rest), 2. M-HIIT group: the medium-interval HIIT group (8 × 2 min Exercise/2 min Rest), 3. Control group: no exercise intervention. All groups carried out the training stage for 8 weeks (three sessions per week), then the detraining stage for 4 weeks in order to investigate the effects induced by different HIIT interventions on inflammation, metabolic adaptation, anti-fatigue and exercise performance, and fat loss.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
36
Inclusion Criteria
  • Recruit people who are overweight or obese (BMI between 24-35) who are 20-65 years old and have no exercise habits in a sitting lifestyle.
Exclusion Criteria
  • If there are any of the following circumstances, they are not allowed to participate in this research and are included in the listing conditions of this case:

    1. Have smoking and drinking habits.
    2. People who have stroke, type 1 and type 2 diabetes, neuromuscular disease, so that they cannot participate in physical activities.
    3. Chronic obstructive lung disease, asthma, interstitial lung disease or alveolar cyst fibrosis.
    4. Metabolic diseases include thyroid disease, kidney disease (kidney, bladder stones) or liver disease.
    5. Those with arrhythmia, a rhythm regulator, severe cardiovascular disease, peripheral vascular disease or cerebrovascular disease.
    6. People with epilepsy and rheumatoid arthritis.
    7. Those who have implanted artificial joints in the past six months and have had recent surgery.
    8. Migraine, acute thrombosis and hernia.
    9. Those who have engaged in strenuous exercise or have muscle aches within 24 hours before the experiment.
    10. People who feel unwell due to other reasons during the experiment.
    11. People with severe food allergies.
    12. Have hospitalization records within three months.
    13. People with cognitive impairment.
    14. Take any drugs that affect the function of the nervous system.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
L-HIITL-HIIT-
M-HIITM-HIIT-
Primary Outcome Measures
NameTimeMethod
Aerobic Capacity TestPrimary Outcomes were measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).

All subjects wore polar heart rate belts (Polar Electro Oy, Kempele, Finland) to monitor maximum heart rate during aerobic capacity testing.

Anti-fatigue performancePrimary Outcomes were measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).

After a standard warm-up, all subjects were assessed with the classical Wingate (WAnT) on a cycloergometer (Monark 894E, Varberg, Sweden) in a 30 s "go all out" ultramax test. The seat height was adjusted to the satisfaction of each participant, and toe clips prevented the feet from slipping off the pedals. Before the initial test, the subjects warmed up for 5 min, and the power was approximately 50 W. After the warm-up, two preparation exercises lasting 3 s, during which the actual test load was 3% of their own body weight, were applied to accustom the participant to resistance. The test started, and the resistance was set on the friction belt of the dynamometer. External loading was estimated individually at 5% body weight. The average relative mean power parameters were recorded.

skinfold thicknessPrimary Outcomes were measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).

The sum of skinfold thickness at seven sites (triceps, chest, subscapular muscle, upper ilium, abdomen, front thigh, and leg) was measured by using a skinfold caliper (Beta Technology, Santa Cruz, California, USA).

Body composition_body fatPrimary Outcomes were measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).

The multi-frequency principle was applied to measure body composition by using a bioelectrical impedance analyzer (BIA) on an InBody 570 device (In-body, Seoul, South Korea). To perform the measurements, after the subjects' palms and soles were removed from the sensors, the subjects stood on the footing electrodes and held the sensing handles with two hands. During the measurements, the subjects kept their arms open and left their bodies at an angle of 30° without speaking or moving. The subjects also fasted for at least 8 h before the test. The body fat were meansure

Secondary Outcome Measures
NameTimeMethod
Glucosewere measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).

Safety is assessed function of Glucose (70\~100 mg/dL)

high-density lipoprotein (HDL)were measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).

Safety is assessed function of blood lipid such as LDL (0\~140mg/dl)

tumor necrosis factor (TNF)-R1were measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).

At designated time points in the recovery period, blood samples were collected with brachial venous catheters. Used commercial kit human TNF-R1 (R \& D SYSTEMS, MN USA) and Elisa reader (PerkinElmer, Massachusetts, USA) for analysis

TNF-R2were measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).

At designated time points in the recovery period, blood samples were collected with brachial venous catheters. Used commercial kit human TNF-R1 (R \& D SYSTEMS, MN USA) and Elisa reader (PerkinElmer, Massachusetts, USA) for analysis

creatine kinase (CK) levelwere measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).

At designated time points in the recovery period, blood samples were collected with brachial venous catheters. Assess serum CK(Creatine Kinase, U/L) to monitor physiological fitness. Serum CK (U/L), were assessed for monitoring physiological adaptation. All biochemical indices were assessed using an autoanalyzer (Hitachi 7060, Tokyo, Japan).

Triglycerideswere measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).

Safety is assessed function of blood lipid such as Triglycerides (\<150 mg/dL)

C-reactive protein (CRP)were measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).

At designated time points in the recovery period, blood samples were collected with brachial venous catheters. Used commercial kit human CRP (Cayman, Mich, USA) and Elisa reader (PerkinElmer, Massachusetts, USA) for analysis

low-density lipoprotein (LDL)were measured before the intervention (at week 0), after eight weeks of HIIT intervention (at week 8), and after the following four weeks of detraining (at week 12).

Safety is assessed function of blood lipid such as LDL (0\~140mg/dl)

Trial Locations

Locations (1)

Taipei Medical University

🇨🇳

Taipei, Taiwan

© Copyright 2025. All Rights Reserved by MedPath